drugset / Trial / NCT05315778
Anti-BCMA CAR T-Cell Therapy for R/R ITP
Phase 2
Unknown
5 enrolled
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy（BCMA CAR-T）for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).
Timeline
- Start
- 2022-01-01
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous anti-BCMA chimeric antigen receptor T cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | autologous anti-BCMA chimeric antigen receptor T cells | Cell therapy | 2e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |